Cargando…

Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination

INTRODUCTION: While antibodies raised by SARS-CoV-2 mRNA vaccines have had compromised efficacy to prevent breakthrough infections due to both limited durability and spike sequence variation, the vaccines have remained highly protective against severe illness. This protection is mediated through cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Taus, Ellie, Hofmann, Christian, Ibarrondo, F. Javier, Gong, Laura S., Hausner, Mary Ann, Fulcher, Jennifer A., Krogstad, Paul, Kitchen, Scott G., Ferbas, Kathie G., Tobin, Nicole H., Rimoin, Anne W., Aldrovandi, Grace M., Yang, Otto O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968837/
https://www.ncbi.nlm.nih.gov/pubmed/36860850
http://dx.doi.org/10.3389/fimmu.2023.1100594
_version_ 1784897582919581696
author Taus, Ellie
Hofmann, Christian
Ibarrondo, F. Javier
Gong, Laura S.
Hausner, Mary Ann
Fulcher, Jennifer A.
Krogstad, Paul
Kitchen, Scott G.
Ferbas, Kathie G.
Tobin, Nicole H.
Rimoin, Anne W.
Aldrovandi, Grace M.
Yang, Otto O.
author_facet Taus, Ellie
Hofmann, Christian
Ibarrondo, F. Javier
Gong, Laura S.
Hausner, Mary Ann
Fulcher, Jennifer A.
Krogstad, Paul
Kitchen, Scott G.
Ferbas, Kathie G.
Tobin, Nicole H.
Rimoin, Anne W.
Aldrovandi, Grace M.
Yang, Otto O.
author_sort Taus, Ellie
collection PubMed
description INTRODUCTION: While antibodies raised by SARS-CoV-2 mRNA vaccines have had compromised efficacy to prevent breakthrough infections due to both limited durability and spike sequence variation, the vaccines have remained highly protective against severe illness. This protection is mediated through cellular immunity, particularly CD8+ T cells, and lasts at least a few months. Although several studies have documented rapidly waning levels of vaccine-elicited antibodies, the kinetics of T cell responses have not been well defined. METHODS: Interferon (IFN)-γ enzyme-linked immunosorbent spot (ELISpot) assay and intracellular cytokine staining (ICS) were utilized to assess cellular immune responses (in isolated CD8+ T cells or whole peripheral blood mononuclear cells, PBMCs) to pooled peptides spanning spike. ELISA was performed to quantitate serum antibodies against the spike receptor binding domain (RBD). RESULTS: In two persons receiving primary vaccination, tightly serially evaluated frequencies of anti-spike CD8+ T cells using ELISpot assays revealed strikingly short-lived responses, peaking after about 10 days and becoming undetectable by about 20 days after each dose. This pattern was also observed in cross-sectional analyses of persons after the first and second doses during primary vaccination with mRNA vaccines. In contrast, cross-sectional analysis of COVID-19-recovered persons using the same assay showed persisting responses in most persons through 45 days after symptom onset. Cross-sectional analysis using IFN-γ ICS of PBMCs from persons 13 to 235 days after mRNA vaccination also demonstrated undetectable CD8+ T cells against spike soon after vaccination, and extended the observation to include CD4+ T cells. However, ICS analyses of the same PBMCs after culturing with the mRNA-1273 vaccine in vitro showed CD4+ and CD8+ T cell responses that were readily detectable in most persons out to 235 days after vaccination. DISCUSSION: Overall, we find that detection of spike-targeted responses from mRNA vaccines using typical IFN-γ assays is remarkably transient, which may be a function of the mRNA vaccine platform and an intrinsic property of the spike protein as an immune target. However, robust memory, as demonstrated by capacity for rapid expansion of T cells responding to spike, is maintained at least several months after vaccination. This is consistent with the clinical observation of vaccine protection from severe illness lasting months. The level of such memory responsiveness required for clinical protection remains to be defined.
format Online
Article
Text
id pubmed-9968837
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99688372023-02-28 Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination Taus, Ellie Hofmann, Christian Ibarrondo, F. Javier Gong, Laura S. Hausner, Mary Ann Fulcher, Jennifer A. Krogstad, Paul Kitchen, Scott G. Ferbas, Kathie G. Tobin, Nicole H. Rimoin, Anne W. Aldrovandi, Grace M. Yang, Otto O. Front Immunol Immunology INTRODUCTION: While antibodies raised by SARS-CoV-2 mRNA vaccines have had compromised efficacy to prevent breakthrough infections due to both limited durability and spike sequence variation, the vaccines have remained highly protective against severe illness. This protection is mediated through cellular immunity, particularly CD8+ T cells, and lasts at least a few months. Although several studies have documented rapidly waning levels of vaccine-elicited antibodies, the kinetics of T cell responses have not been well defined. METHODS: Interferon (IFN)-γ enzyme-linked immunosorbent spot (ELISpot) assay and intracellular cytokine staining (ICS) were utilized to assess cellular immune responses (in isolated CD8+ T cells or whole peripheral blood mononuclear cells, PBMCs) to pooled peptides spanning spike. ELISA was performed to quantitate serum antibodies against the spike receptor binding domain (RBD). RESULTS: In two persons receiving primary vaccination, tightly serially evaluated frequencies of anti-spike CD8+ T cells using ELISpot assays revealed strikingly short-lived responses, peaking after about 10 days and becoming undetectable by about 20 days after each dose. This pattern was also observed in cross-sectional analyses of persons after the first and second doses during primary vaccination with mRNA vaccines. In contrast, cross-sectional analysis of COVID-19-recovered persons using the same assay showed persisting responses in most persons through 45 days after symptom onset. Cross-sectional analysis using IFN-γ ICS of PBMCs from persons 13 to 235 days after mRNA vaccination also demonstrated undetectable CD8+ T cells against spike soon after vaccination, and extended the observation to include CD4+ T cells. However, ICS analyses of the same PBMCs after culturing with the mRNA-1273 vaccine in vitro showed CD4+ and CD8+ T cell responses that were readily detectable in most persons out to 235 days after vaccination. DISCUSSION: Overall, we find that detection of spike-targeted responses from mRNA vaccines using typical IFN-γ assays is remarkably transient, which may be a function of the mRNA vaccine platform and an intrinsic property of the spike protein as an immune target. However, robust memory, as demonstrated by capacity for rapid expansion of T cells responding to spike, is maintained at least several months after vaccination. This is consistent with the clinical observation of vaccine protection from severe illness lasting months. The level of such memory responsiveness required for clinical protection remains to be defined. Frontiers Media S.A. 2023-02-13 /pmc/articles/PMC9968837/ /pubmed/36860850 http://dx.doi.org/10.3389/fimmu.2023.1100594 Text en Copyright © 2023 Taus, Hofmann, Ibarrondo, Gong, Hausner, Fulcher, Krogstad, Kitchen, Ferbas, Tobin, Rimoin, Aldrovandi and Yang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Taus, Ellie
Hofmann, Christian
Ibarrondo, F. Javier
Gong, Laura S.
Hausner, Mary Ann
Fulcher, Jennifer A.
Krogstad, Paul
Kitchen, Scott G.
Ferbas, Kathie G.
Tobin, Nicole H.
Rimoin, Anne W.
Aldrovandi, Grace M.
Yang, Otto O.
Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination
title Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination
title_full Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination
title_fullStr Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination
title_full_unstemmed Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination
title_short Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination
title_sort persistent memory despite rapid contraction of circulating t cell responses to sars-cov-2 mrna vaccination
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968837/
https://www.ncbi.nlm.nih.gov/pubmed/36860850
http://dx.doi.org/10.3389/fimmu.2023.1100594
work_keys_str_mv AT tausellie persistentmemorydespiterapidcontractionofcirculatingtcellresponsestosarscov2mrnavaccination
AT hofmannchristian persistentmemorydespiterapidcontractionofcirculatingtcellresponsestosarscov2mrnavaccination
AT ibarrondofjavier persistentmemorydespiterapidcontractionofcirculatingtcellresponsestosarscov2mrnavaccination
AT gonglauras persistentmemorydespiterapidcontractionofcirculatingtcellresponsestosarscov2mrnavaccination
AT hausnermaryann persistentmemorydespiterapidcontractionofcirculatingtcellresponsestosarscov2mrnavaccination
AT fulcherjennifera persistentmemorydespiterapidcontractionofcirculatingtcellresponsestosarscov2mrnavaccination
AT krogstadpaul persistentmemorydespiterapidcontractionofcirculatingtcellresponsestosarscov2mrnavaccination
AT kitchenscottg persistentmemorydespiterapidcontractionofcirculatingtcellresponsestosarscov2mrnavaccination
AT ferbaskathieg persistentmemorydespiterapidcontractionofcirculatingtcellresponsestosarscov2mrnavaccination
AT tobinnicoleh persistentmemorydespiterapidcontractionofcirculatingtcellresponsestosarscov2mrnavaccination
AT rimoinannew persistentmemorydespiterapidcontractionofcirculatingtcellresponsestosarscov2mrnavaccination
AT aldrovandigracem persistentmemorydespiterapidcontractionofcirculatingtcellresponsestosarscov2mrnavaccination
AT yangottoo persistentmemorydespiterapidcontractionofcirculatingtcellresponsestosarscov2mrnavaccination